新通药物64岁首席医学官金伟丽拥有美国永居权，年薪402万元是董事长四倍

Core Viewpoint - Xintong Pharmaceutical Research Co., Ltd. has received approval for its IPO on the Sci-Tech Innovation Board, focusing on drug development for major liver diseases such as hepatitis B, metabolic dysfunction-related fatty liver disease, and liver cancer [1]. Company Overview - Established in May 2000, Xintong Pharmaceutical is a high-tech enterprise with over 20 years of experience in drug research and development, specifically targeting liver diseases [1]. - The company currently has eight core products for liver disease treatment, including one approved innovative drug and several others in various stages of clinical trials [1]. Financial Performance - Revenue figures for Xintong Pharmaceutical from 2022 to 2025 are as follows: - 2022: 1.10 million - 2023: 11.98 million - 2024: 30.19 million - 2025 (first half): 9.77 million [2][3]. - Net losses for the same periods are: - 2022: 53.87 million - 2023: 62.29 million - 2024: 79.36 million - 2025 (first half): 13.20 million [2][3]. Product Pipeline - The company has one Class 1 innovative drug, "Xinshi Mu®," which is the world's first targeted hepatitis B treatment developed using a liver-targeting technology platform, expected to be included in the national medical insurance directory by the end of 2025 [1]. Management Team - The company is led by Zhang Dengke, who serves as the Chairman and General Manager, and Jin Weili, who is the Chief Medical Officer [5]. - Zhang Dengke holds 46.45% of the company's shares directly and controls an additional 7.42% indirectly, totaling 53.86% [2][5]. Compensation - In 2024, Zhang Dengke received a salary of 1.015 million, while Jin Weili earned 4.021 million [6][7].